Castle Creek Biosciences Announces $75 Million Investment to Advance Development of Multiple Gene Therapy Candidates for Rare Diseases
News, Events & Presentations

Castle Creek Biosciences Announces $75 Million Investment to Advance Development of Multiple Gene Therapy Candidates for Rare Diseases

Leveraging proprietary technology and manufacturing platform to develop transformative gene therapies for multiple rare diseases with high unmet needsPipeline led by Phase 3 gene therapy candidate for treatment of recessive dystrophic epidermolysis bullosa (RDEB), with a BLA filing targeted for 2021Backed by world-class group of biotech operators and investorsCastle Creek Biosciences, Inc., a privately held, […]

Read More

Corporate Fact Sheet

Castle Creek Biosciences, Inc., a privately held company located in Exton, PA, is focused on developing and commercializing personalized gene therapies for patients with rare and serious genetic diseases. Castle Creek Biosciences is a portfolio company of Paragon Biosciences.

Read More

Rare Daily’s RARECast

“Acquisition Combines Two Pipelines for Rare Skin Diseases” John Maslowski, CEO, Castle Creek Biosciences

Read More

Philadelphia Magazine’s NextHealth PHL

NextUp: “The Company Using Gene Therapy to Cure Rare Skin Conditions” John Maslowski, CEO, Castle Creek Biosciences

Read More

Rare Disease Innovation and Partnering Summit 2020

Boston, June 24-26

Read More

Annual International Society for Pharmaceutical Engineering Symposium

Philadelphia, May 14

Read More

23rd Annual Meeting American Society of Gene & Cell Therapy

Boston, May 12-16

Read More